The clinical trial results 25 September 2026 span Sjögren’s, urticaria, IgA nephropathy, obesity, cutaneous lupus and Alzheimer’s psychosis.
Amgen’s dazodalibep met its primary endpoint in systemic Sjögren’s disease. Celldex’s barzolvolimab met its primary and all key secondary endpoints in twin chronic spontaneous urticaria trials. Roche’s sefaxersen cut proteinuria in an interim IgA nephropathy analysis. Viking Therapeutics’ VK2735 held most weight loss on less frequent maintenance dosing in obesity. Two readouts missed. Immunovant’s IMVT-1402 failed in cutaneous lupus erythematosus, and Acadia’s remlifanserin missed its primary endpoint in Alzheimer’s disease psychosis. Here, Life Science Daily News brings you the week’s most significant readouts.
Dazodalibep Meets Its Primary Endpoint in the Phase 3 OASIZ 301 Study in Systemic Sjögren’s Disease
Amgen announced on 22 September 2026 that dazodalibep met the primary endpoint of the Phase 3 OASIZ 301 study. The study showed a statistically significant improvement versus placebo at week 48. Improvement was measured on the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI). The company said the effect emerged as early as week 4 and was sustained through week 48. Amgen has not yet disclosed the point change or p-value. It plans to present detailed data at an upcoming medical meeting.
OASIZ 301 (NCT06104124) is a randomised, double-blind, placebo-controlled study in approximately 621 adults. All had moderate-to-severe systemic Sjögren’s disease, defined as an ESSDAI score of 5 or higher. Amgen describes dazodalibep as a potential first-in-class CD40 ligand antagonist fusion protein. It is designed to disrupt interactions between T cells, B cells and other antigen-presenting cells. There are no FDA-approved medicines for Sjögren’s disease, according to Amgen. The most common adverse events were nasopharyngitis, urinary tract infection, hypertension and infusion-related reactions. Each occurred in 5 per cent or more of patients, at a higher rate than placebo. Most were mild to moderate, and Amgen reported no imbalance in thromboembolic events or opportunistic infections. A second Phase 3 study, OASIZ 303, is expected to complete in the fourth quarter of 2026. It evaluates patients with high symptom burden and low systemic disease activity.
Barzolvolimab Meets Primary and All Key Secondary Endpoints in Twin Phase 3 EMBARQ Studies in Chronic Spontaneous Urticaria
Celldex Therapeutics announced on 22 September 2026 positive topline results from EMBARQ-CSU1 and EMBARQ-CSU2. Both Phase 3 studies enrolled patients with chronic spontaneous urticaria (CSU) inadequately controlled by antihistamines. Each met its primary endpoint and all key secondary endpoints at week 12. The Urticaria Activity Score over 7 days (UAS7) fell by 20.2 points on 150 mg every four weeks. With 300 mg every eight weeks, it fell by 20.5 points (CSU1) and 19.7 points (CSU2). Placebo reductions were 10.7 points (CSU1) and 11.4 points (CSU2), with p<0.00001 for each comparison. Complete response, a UAS7 score of zero, was reached by 42 to 46 per cent of treated patients. The placebo rate was 9 to 13 per cent, and response rates were sustained or improved through week 24.
The two trials together randomised 1,939 patients (NCT06445023 and NCT06455202). Barzolvolimab is a humanised monoclonal antibody that binds the KIT receptor on mast cells. It works by a different mechanism to omalizumab, the longest-established biologic for antihistamine-refractory CSU. Celldex said the safety profile through 24 weeks was consistent with prior Phase 2 experience. The release did not report adverse event rates. Treatment continues to 52 weeks, and the company expects to submit a Biologics License Application in 2027.
Sefaxersen Cuts Proteinuria in Interim Phase 3 IMAgINATION Analysis in IgA Nephropathy
Roche announced on 23 September 2026 positive interim results from the Phase 3 IMAgINATION study of sefaxersen. The study is in adults with primary IgA nephropathy (IgAN) at high risk of progression. Roche says up to 50 per cent of people with IgAN reach end-stage kidney disease within 20 years of diagnosis. The study met its primary endpoint, change in urine protein-to-creatinine ratio (UPCR) at week 37 versus placebo. Roche described the proteinuria reduction as statistically significant and clinically meaningful. No figures or p-values were disclosed. Roche said the interim data will be presented at an upcoming medical congress.
IMAgINATION (NCT05797610) randomised 459 participants 1:1 to sefaxersen or placebo for 105 weeks. Sefaxersen is an antisense oligonucleotide, licensed by Roche from Ionis Pharmaceuticals. It inhibits production of complement factor B in the liver, blocking the alternative complement pathway implicated in IgAN. The study continues blinded to assess change in estimated glomerular filtration rate (eGFR) at week 105. That is the measure now separating IgAN medicines, as LSDN’s IgAN full approval analysis sets out.Roche said the safety profile was consistent with previously reported data, with no new safety signals. The interim results will be shared with health authorities. Roche said the goal is to bring the treatment to patients as soon as possible.
VK2735 Maintenance Study Shows Most Weight Loss Retained With Less Frequent Dosing
Viking Therapeutics announced on 22 September 2026 topline results from its VK2735-102 maintenance study in adults with obesity. VK2735 is a dual agonist of the GLP-1 and GIP receptors. The study’s stated objectives were safety, tolerability and pharmacokinetics, and all weight endpoints were exploratory. Over a 21-week induction phase, weekly VK2735 produced weight loss of about 16 to 19 per cent. Placebo produced about 0 per cent (p<0.0001). Patients then switched to less frequent dosing for 12 weeks. Every-other-week dosing retained 90 per cent of weight loss across cohorts, and up to 97 per cent in one cohort. Monthly dosing retained 85 per cent across cohorts, and up to 90 per cent in one cohort. Patients switched to placebo retained 61 per cent.
Individual maintenance cohorts contained between 10 and 16 patients. An exploratory group that stayed on weekly 17.5 mg dosing reached 21.7 per cent weight loss by week 33. Viking said no plateau was observed in that group of 13 patients. The study enrolled approximately 180 adults with a body mass index of 30 kg/m2 or higher. Gastrointestinal adverse event rates during maintenance were similar to placebo, and discontinuations were low, the company said. Viking plans to explore oral maintenance dosing in a second part of the current study.
IMVT-1402 Misses Its Primary Endpoint in a Proof-of-Concept Cutaneous Lupus Study, Immunovant Discontinues the Indication
Immunovant announced on 23 September 2026 topline results from Period 1 of a proof-of-concept study of IMVT-1402 (imeroprubart). The study was in cutaneous lupus erythematosus (CLE). It did not achieve statistical significance on its primary endpoint. The endpoint used the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score. It measured percentage change from baseline at week 12. The company did not disclose a p-value. Immunovant said numerical trends favoured IMVT-1402 across multiple endpoints. Patients with deeper IgG reductions were more likely to show improved clinical responses, it added. The company said the results did not meet its internal bar to continue in CLE.
The randomised, placebo-controlled study (NCT06980805) enrolled 57 adults with CLE. IMVT-1402 is an anti-FcRn antibody that lowers circulating IgG levels. Immunovant said the safety and tolerability profile was consistent with prior studies. It is stopping CLE development, citing the clinical results and the competitive landscape. IMVT-1402 remains in development for Graves’ disease, difficult-to-treat rheumatoid arthritis and myasthenia gravis. It is also in development for chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease. Immunovant said all other development timelines remain on track.
Remlifanserin Misses Its Primary Endpoint in the RADIANT Study in Alzheimer’s Disease Psychosis
Acadia Pharmaceuticals announced on 24 September 2026 topline results from the Phase 2 portion of RADIANT. RADIANT is an operationally seamless Phase 2/3 programme of remlifanserin in Alzheimer’s disease psychosis. The primary endpoint was change from baseline on the SAPS-H+D hallucinations and delusions scale at week 6. At 60 mg, scores improved by 12.6 points versus 10.4 points on placebo (p=0.0603). The difference did not reach statistical significance. On the key secondary CGI-S-ADP severity scale, 60 mg scored -1.3 versus -0.9 on placebo. Acadia reported that p-value, 0.0077, as nominal. The 30 mg dose showed minimal improvement over placebo, the company said. Acadia described the results as “Phase 3 enabling.”
The randomised, double-blind, placebo-controlled study tested once-daily 60 mg and 30 mg doses against placebo. Acadia reported adverse event rates similar to placebo across both doses. It found no signal of QT prolongation versus placebo. The company said the data suggest no negative impact on motor symptoms or cognition. Acadia will continue enrolling its two ongoing Phase 3 studies in the indication. It is amending the Phase 3 programme, including removal of the 30 mg arm. Detailed results are due at the Clinical Trials on Alzheimer’s Disease conference in November.
Looking Ahead
This week’s clinical trial results 25 September 2026 lean towards diseases with few or no approved options. Dazodalibep adds a second late-stage contender in systemic Sjögren’s disease. Novartis’s ianalumab is further along, with FDA Breakthrough Therapy designation granted in January 2026. Novartis planned global regulatory submissions for ianalumab from early 2026. Full ESSDAI data for dazodalibep are still to come.
Barzolvolimab’s replication across two large trials strengthens the case for a mast cell-targeted option in CSU. That market already includes omalizumab and Novartis’s oral BTK inhibitor remibrutinib, approved by the FDA in September 2025. Sefaxersen’s interim result adds to positive complement-pathway data in kidney disease, though full data are awaited. Viking’s maintenance cohorts were small and short. They still address a live question in obesity: holding weight loss with fewer injections.
The week’s two misses show that a favourable safety profile is not the same as efficacy. Immunovant has stopped development of IMVT-1402 in cutaneous lupus. Acadia is continuing in Alzheimer’s disease psychosis, citing a nominally significant secondary endpoint after missing its primary. Life Science Daily News will continue to cover the readouts that matter across the global life sciences pipeline. Read the 18 September 2026 clinical trials roundup.














